{"prompt": "['GB001, Inc.', 'GB001', 'Protocol GB001-2101', 'Version 5.0, 16 Apr 2020', 'Highly Effective Methods That Have Low User Dependency', 'Implantable progestogen-only hormone contraception associated with inhibition of ovulationb', 'Intrauterine device (IUD)', 'Intrauterine hormone-releasing system (IUS)b', 'Bilateral tubal occlusion', 'Vasectomized partner', '(Vasectomized partner is a highly effective contraceptive method provided that the partner is the', 'sole sexual partner of the woman of childbearing potential and the absence of sperm has been', 'confirmed. If not, an additional highly effective method of contraception should be used.', 'Spermatogenesis cycle is approximately 90 days.)', 'Highly Effective Methods That Are User Dependent', 'Combined (estrogen- and progestogen-containing) hormonal contraception associated with', 'inhibition of ovulation', '- oral', '- intravaginal', '- transdermal', '- injectable', 'Progestogen-only hormone contraception associated with inhibition of ovulationb', '- oral', '- injectable', 'Sexual abstinence', '(Sexual abstinence is considered a highly effective method only if defined as refraining from', 'heterosexual intercourse during the entire period of risk associated with the IP. The reliability of', 'sexual abstinence needs to be evaluated in relation to the duration of the study and the preferred and', 'usual lifestyle of the subject.)', 'a', 'Failure rate of < 1% per year when used consistently and correctly. Typical use failure rates differ from those', 'when used consistently and correctly', 'b', 'If locally required, in accordance with Clinical Trial Facilitation Group (CTFG) guidelines, acceptable', 'contraceptive methods are limited to those which inhibit ovulation as the primary mode of action', 'Note: Periodic abstinence (calendar, symptothermal, post-ovulation methods), withdrawal (coitus interruptus),', 'spermicides only, and lactational amenorrhoea method (LAM) are not acceptable methods of contraception for', 'this study. Male condom and female condom should not be used together (due to risk of failure with friction).', '62', 'CONFIDENTIAL']['GB001, Inc.', 'GB001', 'Protocol GB001-2101', 'Version 5.0, 16 Apr 2020', 'Collection of Pregnancy Information', 'Female Subjects who become pregnant', 'The investigator will collect pregnancy information on any female subject who', 'becomes pregnant while participating in this study. Information will be recorded on', 'the appropriate form and submitted to the sponsor within 24 hours of learning of a', \"subject's pregnancy.\", 'The subject will be followed to determine the outcome of the pregnancy. The', 'investigator will collect follow-up information on the subject and the neonate and the', 'information will be forwarded to the sponsor. Generally, follow-up will not be', 'required for longer than 6 to 8 weeks beyond the estimated delivery date. Any', 'termination of pregnancy will be reported, regardless of fetal status (presence or', 'absence of anomalies) or indication for the procedure.', 'While pregnancy itself is not considered to be an AE or SAE, any pregnancy', 'complication or elective termination of a pregnancy will be reported as an AE', 'or', 'SAE. A spontaneous abortion is always considered to be an SAE and will be reported', 'as such. Any post-study pregnancy related SAE considered reasonably related to the', 'study intervention by the investigator will be reported to the sponsor as described in', 'Section 10.3.5. While the investigator is not obligated to actively seek this', 'information in former study subjects, he or she may learn of an SAE through', 'spontaneous reporting.', 'Any female subject who becomes pregnant while participating in the study will', 'discontinue IP or be withdrawn from the study.', '63', 'CONFIDENTIAL']['GB001, Inc.', 'GB001', 'Protocol GB001-2101', 'Version 5.0, 16 Apr 2020', '10.5.', 'Appendix 5: Genetics', 'Use and Analysis of DNA', \"Genetic variation may impact a subject's response to IP, susceptibility to, and severity\", 'and progression of disease. Variable response to IP may be due to genetic', 'determinants that impact drug absorption, distribution, metabolism, and excretion;', 'mechanism of action of the drug; disease etiology; and/or molecular subtype of the', 'disease being treated. Therefore, where local regulations and IRB/IEC allow, a', 'biosample may be collected for DNA analysis from consenting subjects.', 'DNA samples may be used for research related to the relationship between safety,', 'efficacy, and exposure parameters collected in this study, as they related to placebo,', 'GB001, CRS, and related diseases. They may also be used to develop tests/assays', 'including diagnostic tests related to GB001 and DP2 inhibitors and/or atopic disease.', 'Genetic research may consist of the analysis of candidate polymorphisms,', 'prespecified in the statistical analysis plan.', 'The samples may be analyzed as part of a multi-study assessment of genetic factors', 'involved in the response to GB001 of this class to understand study disease or related', 'atopic conditions.', 'The results of genetic analyses may be reported in a separate study summary.', 'The Sponsor will store the samples in a secure storage space with adequate measures', 'to protect confidentiality.', 'The samples will be retained while research on GB001 continues but no longer than', '8 years or other period as per local requirements.', '64', 'CONFIDENTIAL']\n\n###\n\n", "completion": "END"}